Cite
HARVARD Citation
Reifsnider, O. et al. (2022). Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes, obesity & metabolism. 24 (4), pp. 652-661. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Reifsnider, O. et al. (2022). Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes, obesity & metabolism. 24 (4), pp. 652-661. [Online].